Synairgen plc (LON:SNG) chief executive Richard Marsden tells Proactive Investors that it’s “not the end of the road” for its asthma treatment after AstraZeneca (LON:AZN) announced it would review how to proceed with the phase IIa trial of the drug.
AstraZeneca decided to stop the trial as fewer severe cases were found amongst patients than researchers had expected.
“It’s not the end of the road for the drug at all,” Marsden says.
The pharma giant will analyse the data generated so far in the trial at the start of next year, and Marsden thinks this could be a good thing.
“AstraZeneca [is] going to look at the data in the first quarter of next year, which is probably earlier than we had initially expected.”
“If anything, this is all happening earlier in the year than we had anticipated, so this could be good news.”